In contrast, lung cancers exhibit prognostic variations based on the presence of EGFR and KRAS, influenced in part due to historic availability of highly active EGFR tyrosine kinase inhibitors; in the breast, presence or absence of estrogen receptor expression dictates therapeutic options. This evidence concerns the gene EGFR and lung carcinoma.